var data={"title":"Rilpivirine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rilpivirine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/472437?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">see &quot;Rilpivirine: Drug information&quot;</a> and <a href=\"topic.htm?path=rilpivirine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rilpivirine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891404\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Edurant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13265550\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Edurant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27640844\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27640849\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">see &quot;Rilpivirine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;12 years or &lt;35 kg: Not recommended for use; no dosing recommendations available</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &ge;12 years and &ge;35 kg: Oral: 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>HIV-1 infection, treatment:</b> Oral: 25 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant therapy with rifabutin:</b> Children &ge;12 years and Adolescents: Increase to 50 mg once daily in patients on concomitant rifabutin. Decrease to 25 mg once daily when rifabutin is stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment: </b>Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate renal impairment: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe or end-stage renal impairment: Use with caution; guidelines suggest no dosage adjustment necessary (HHS [adult], 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis/peritoneal dialysis: Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment: </b>Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891454\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Edurant: 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891405\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27640850\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Swallow tablet whole with water. Administer with a normal- to high-calorie meal; taking with a protein supplement drink alone is not adequate. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891423\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep in original container; protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27640845\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infections in treatment-naive patients with HIV-1 RNA &le;100,000 copies/mL at the start of therapy in combination with other antiretroviral agents (FDA approved in ages &ge;12 years and weighing &ge;35 kg and adults). <b>Note:</b> HIV regimens consisting of three antiretroviral agents are strongly recommended.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708060\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891416\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, depression (more common in children and adolescents), dizziness (more common in children and adolescents), drowsiness (children and adolescents), fatigue, headache (more common in children and adolescents), insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased plasma cortisol (more common in children and adolescents; decrease from baseline via ACTH stimulation test; clinical significance is unknown), increased LDL cholesterol, increased serum cholesterol, increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (more common in children and adolescents), nausea (more common in children and adolescents), vomiting (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Conjunctivitis, DRESS syndrome, hepatitis, hypersensitivity reaction, localized vesiculation, nephrotic syndrome, suicidal ideation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891411\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin), antimycobacterials (rifampin, rifapentine), proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole), systemic dexamethasone (more than a single dose), or St John's wort.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to rilpivirine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891412\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depressive disorders: May cause depression, depressed mood, dysphoria, mood changes, negative thoughts, suicide attempts, or suicidal ideation; if changes are noted, seek professional intervention immediately; reevaluate risk versus benefit of continued rilpivirine therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity:  Has been reported during use. Patients with significant transaminase elevations or hepatitis B or C prior to treatment may be at greater risk for hepatic adverse events. Hepatotoxicity has occurred in a few adult patients with no prior hepatic disease or risk factors.  Baseline and periodic laboratory LFT evaluation during therapy is recommended for patients with pre-existing risk factors;  also consider LFT monitoring in patients without identifiable hepatic disease risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and severe skin reactions have been reported, including severe rash or rash accompanied by fever, blisters, mucosal involvement, conjunctivitis, facial edema, angioedema, hepatitis or eosinophilia, or drug reaction with eosinophilia and systemic symptoms (DRESS) with rilpivirine-containing regimens. Some skin reactions were accompanied by constitutional symptoms (eg, fever); other skin reactions were associated with organ dysfunction (eg, hepatic serum biochemistry elevations).  In clinical trials, treatment-related rashes &ge; Grade 2 were reported in 3% of patients. Most rashes were Grade 1 or 2 and occurred within the first 4 to 6 weeks of therapy. No Grade 4 rashes were reported. Monitor laboratory parameters and clinical status; discontinue if any hypersensitivity or skin rash develop. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QTc prolongation: Doses &gt;25 mg daily (ie, 75 mg daily, 300 mg daily) have been associated with QTc prolongation; use caution when coadministering with a drug with a known risk of torsades de pointes (HHS [adult] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use in adolescent and adult HIV-1 patients with a pre-ART of CD4 count &lt;200 cells/mm<sup>3</sup> and/or HIV RNA &gt;100,000 copies/mL (HHS [adult] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44519785\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In trials, the reported incidence of adverse reactions was higher in pediatric subjects  than in adults; 52.8% overall, most were grade 1 or 2. Reported adverse reactions for pediatric patients (in at least two subjects, ages 12 to 18 years) include: Headache (19.4% vs 3% in adults), depression (19.4% vs. 4 to 9 % in adults), somnolence (13.9%), nausea (11.1% vs 1% in adults), dizziness (8.3% vs 1% in adults), abdominal pain (8.3% vs 2% in adults), vomiting (5.6% vs 1% in adults), and rash (5.6% vs 3% in adults). For depressive disorders, the incidence of Grade 3 and 4 depressive disorders (regardless of causality) was 5.6% (vs 1% in adult studies). None of these pediatric patients discontinued therapy due to their depressive symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300000\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12931828\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104179&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Rilpivirine. Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine. Administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Rilpivirine may decrease the absorption of Didanosine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Didanosine may decrease the absorption of Rilpivirine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food.  Management: Administer didanosine on an empty stomach at least 2 hours before or 4 hours after rilpivirine, due to the requirement that rilpivirine be administered with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergonovine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Rilpivirine. Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Rilpivirine. Rilpivirine may decrease the serum concentration of Ketoconazole (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Rilpivirine. Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Rilpivirine. Management: Increase the rilpivirine adult dose to 50 mg/day during rifabutin treatment. Decrease back to 25 mg/day following rifabutin discontinuation.  Use of rifabutin with the emtricitabine/rilpivirine/tenofovir alafenamide combination product is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Rilpivirine.<b> Exceptions: </b>Rifabutin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891421\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption increased by ~40% when taken with a normal- to high-calorie meal. Management: Administer with a normal- to high-calorie meal. Administration with a protein supplement drink alone does not increase absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit products: Grapefruit products may inhibit CYP3A4-mediated metabolism of rilpivirine and increase its exposure. Management: Avoid grapefruit products during therapy; if these products are consumed monitor for increased effects/toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891408\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Rilpivirine has moderate to high placental transfer. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI therapy; it is not known if pregnancy increases this risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines recommend rilpivirine as a component in alternative regimens for initial use in antiretroviral-na&iuml;ve pregnant females with a pre-treatment HIV RNA &le;100,000 copies/mL and CD4 cell count &ge;200 cells/mm<sup>3</sup>. The pharmacokinetics are highly variable in pregnancy; data is insufficient to recommended pregnancy specific dosing; however, viral loads should be monitored more frequently when standard doses are used in pregnant females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27640851\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Every 6 to 12 months: Lipid panel and urinalysis. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for depressive disorders, QTc prolongation risk (use of concomitant medications that may increase risk), signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, skin rash, or hypersensitivity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891424\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a non-nucleoside reverse transcriptase inhibitor, rilpivirine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities, including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12891426\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pharmacokinetic data in pediatric patients 12 to &lt;18 years reported to be similar to that in adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Increased 40% with a meal (normal-to-high calorie)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99.7% (primarily albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, primarily by CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~50 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 4 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (85%, ~25% as unchanged drug); urine (~6%; &lt;1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27640852\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Rilpivirine has been shown in several studies to be noninferior to efavirenz in treatment-naive HIV-1 patients. Efficacy data in clinical studies exist for up to 96 weeks. Patients with CD4+ counts &lt;200 cells/mm<sup>3</sup> (regardless of HIV-1 RNA at the start of therapy) are more likely to experience virologic failure (defined as HIV-1 RNA &ge;50 copies/mL) than patients with CD4+ counts &ge;200 cells/mm<sup>3</sup>.  Additionally, patients with increased HIV-1 viral loads at treatment initiation (HIV-1 RNA &gt;100,000 copies/mL) are more likely to develop virologic failure. Increased viral load patients also are more likely to develop rilpivirine-resistance, tenofovir and emtricitabine/lamivudine resistance and NNRTI class cross-resistance. Rilpivirine resistance patterns are very similar to those of etravirine (including cross resistance with single substitutions at K101P, Y181I, and Y181V) (Azijn 2010). In rilpivirine-treated patients who experience virologic failure, rilpivirine-resistant mutations are very common (HHS [adult] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322901\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Edurant Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $1,251.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14190115\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Edurant (AT, AU, BB, BE, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, IE, IL, IS, JP, KR, LT, LU, MT, MY, NL, NO, NZ, PL, PT, RO, SE, SG, SI, SK, TH, TR, ZW);</li>\n      <li>Edyurant (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Azijn H, Tirry I, Vingerhoets J, et al, &ldquo;TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active Against Wild-Type and NNRTI-Resistant HIV-1,&rdquo; <i>Antimicrob Agents Chemother</i>, 2010, 54(2):718-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-pediatric-drug-information/abstract-text/19933797/pubmed\" target=\"_blank\" id=\"19933797\">19933797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edurant tablets (rilpvirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated August 6, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Accessed December 30, 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104179 Version 49.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12891404\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13265550\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F27640844\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F27640849\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F12891454\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F12891405\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27640850\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F12891423\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F27640845\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708060\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F12891416\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F12891411\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F12891412\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F44519785\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300000\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F12931828\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F12891421\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12891408\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27640851\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F12891424\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F12891426\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F27640852\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322901\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14190115\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/104179|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">Rilpivirine: Drug information</a></li><li><a href=\"topic.htm?path=rilpivirine-patient-drug-information\" class=\"drug drug_patient\">Rilpivirine: Patient drug information</a></li></ul></div></div>","javascript":null}